DelveInsight’s “Cutaneous Lupus Erythematosus – Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan, and China.
Key Highlights Cutaneous Lupus Erythematosus Market
-
Key Companies working in the Cutaneous Lupus Erythematosus market are Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Biogen, Sanofi and many others
-
Key Therapies working in the Cutaneous Lupus Erythematosus market include litifilimab (BIIB059), daxdilimab (VIB7734), and many others.
-
The market size for the Cutaneous Lupus Erythematosus market is USD 580 Million in 2022.
-
The CAGR for the Cutaneous Lupus Erythematosus market is 7.2 %
Cutaneous Lupus Erythematosus Overview
Cutaneous Lupus Erythematosus is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus, where the symptoms are restricted to the skin. Lupus Erythematosus (LE) is a chronic, autoimmune disease that affects multiple body organs and systems with a broad spectrum of symptoms. About the skin, there are lupus-specific skin lesions and non-specific skin lesions. Cutaneous Lupus Erythematosus and severe systemic LE are on one end of the spectrum. Both of them can occur together and separately. There are three broad types of cutaneous lupus: Acute, Subacute, and Chronic Cutaneous Lupus Erythematosus. The prototypical example of acute cutaneous lupus is the malar rash. Subacute cutaneous lupus usually involves rashes in sun-exposed areas, and this generally does not lead to scarring. Chronic cutaneous lupus can be subdivided into several cutaneous findings, including discoid, tumidus, profundus, and chilblains. The hallmark condition of chronic cutaneous lupus is discoid lupus erythematosus
Cutaneous Lupus Erythematosus Epidemiology Insights
-
The Cutaneous Lupus Erythematosus diagnosed prevalent cases in the United States were around 452,000 cases in 2022.
-
Among the EU4 countries, the UK accounted for the largest number of Cutaneous Lupus Erythematosus cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
-
According to DelveInsight estimates, Japan had around 19,055 and 46,652 diagnosed prevalent male and female cases, respectively, in 2022. These cases are projected to increase during the forecasted period.
-
In China, the total Cutaneous Lupus Erythematosus diagnosed prevalent cases by severity were 352,375, 250,728, and 74,541 in mild, moderate, and severe, respectively, in 2022, which are likely to increase during the forecasted period.
-
It has been observed that the prevalence of Cutaneous lupus erythematosus is higher in CCLE (~73%) compared to SCLE (18%) and ACLE (15%) in the 7MM and China.
-
In the 7MM and China, the total treated cases of Cutaneous lupus erythematosus were ~888,700 in 2022, which are likely to increase to ~1,226,800 cases, respectively, by 2032.
Click here to learn more about the Cutaneous Lupus ErythematosusMarket Landscape
The Report Covers the Cutaneous Lupus Erythematosus Epidemiology Segmented by:
-
Cutaneous Lupus Erythematosus prevalent cases
-
Cutaneous Lupus Erythematosus incident cases
-
Cutaneous Lupus Erythematosus treatment cases
-
Cutaneous Lupus Erythematosus diagnosed cases
Cutaneous Lupus Erythematosus Market Outlook
The Cutaneous Lupus Erythematosus treatment market in the US is entering a new era with changing dynamics. Apart from antimalarial, no targeted drugs have been approved by the US FDA to treat Cutaneous Lupus Erythematosus. The current treatment approach is concentrated on symptomatic management of the disease burden with off-label therapies and considering recommended general protective agents.
It is worth mentioning that the 2021 British Association of Dermatologists Guidelines for the Management of People with Cutaneous Lupus Erythematosus presently recommends the treatment for moderate-severe Cutaneous Lupus Erythematosus includes starting treatment with topical glucocorticoids and calcineurin inhibitors for the mild Cutaneous Lupus Erythematosus. For moderate-severe Cutaneous Lupus Erythematosus patients, recommended therapies include systemic glucocorticoids, systemic immunomodulators, biologics, and others. Moreover, antimalarials will be added as approved treatment agents.
The current Cutaneous Lupus Erythematosus market has been segmented into different commonly used drugs based on the prevailing treatment pattern across the 7MM and China, presenting minor variations in the overall prescription pattern. Glucocorticoids, Immunomodulators, biologics, etc., are the major drugs covered in the forecast model.
The expected launch of upcoming Cutaneous Lupus Erythematosus therapies and greater integration of early patient screening, medication in secondary care and other clinical settings, research on best methods for implementation, and an upsurge in awareness will eventually facilitate the development of effective treatment options. However, there are a few roadblocks regarding the timely diagnosis and treatment of these patients; for instance, generics dominate a major share of the market being used as off-label therapy. These factors often become a hindrance when adopting newer therapies
Key Companies Working in the Cutaneous Lupus Erythematosus Market
-
Hoth Therapeutics
-
Centessa Pharmaceuticals
-
Bristol-Myers Squibb
-
Biogen
-
Sanofi
-
Hoth Therapeutics
-
Zylo Therapeutics
And many others
Cutaneous Lupus Erythematosus Therapies Covered and Analyzed in the Report
-
SOTYKTU (deucravacitinib)
-
GSK2646264
-
Anifrolumab
-
DS-7011a
-
Edecesertib
-
Etanercept
And many others
Learn more about the Key Companies and Emerging Therapies in the Cutaneous Lupus Erythematosus Market
Table of Contents
-
Key Insights
-
Cutaneous Lupus Erythematosus Introduction
-
Executive Summary of Cutaneous Lupus Erythematosus
-
Disease Background and Overview
-
Epidemiology and patient population
-
Cutaneous Lupus Erythematosus Emerging Therapies
-
Cutaneous Lupus Erythematosus Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Cutaneous Lupus Erythematosus Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services